Document Detail


Human lymphoblastoid interferon for hairy cell leukemia: results from the Italian Cooperative Group.
MedLine Citation:
PMID:  3669757     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since April 1985, 82 patients with HCL entered a multicenter study using lymphoblastoid alpha-interferon; 51 (including 15 who failed splenectomy and 24 with substantial splenomegaly) enrolled before April 1986 are evaluated in this study. The patients were treated with 3 mega units daily subcutaneously until complete or partial response and were thereafter randomly allocated to a maintenance regime of 3 mega units/week or to observation only. Ten cases had a complete response, 18 a partial response, and 15 a minimal response. Two patients had no response, two interrupted therapy due to major toxicity (toxic hepatitis and thrombocytopenia), six died before completing 1 month of therapy of sepsis, and two died of myocardial infarction. In the two groups of splenectomized and nonsplenectomized patients the mean time to hemoglobin recovery was 8.5 and 6.5 weeks, respectively, the neutrophil count recovery was 6.5 and 9.3 weeks, and the time to platelet count recovery was 4.0 and 5.4 weeks, respectively. No significant differences in recovery time and response rate were observed between the two groups. In 31 out of 32 patients with substantial splenomegaly the spleen became either inpalpable (18) or significantly smaller (13). This study confirms the responsiveness of HCL to IFN in nonsplenectomized patients with high tumor burdens and is therefore recommended as a first-line therapy.
Authors:
E E Damasio; C Bernasconi; G L Castoldi; T Chisesi; M Federico; T Lamparelli; F Lauria; G Pagnucco; L Resegoti; E Rossi
Related Documents :
16432457 - Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 a...
21300617 - Demographic disparities in patterns of care and survival outcomes for patients with res...
11996477 - Outpatient treatment with subcutaneous histamine dihydrochloride in combination with in...
18528297 - Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patient...
20440857 - Treatment outcome of localized helicobacter pylori-negative low-grade gastric malt lymp...
1827717 - Postremission chemotherapy in adult acute non-lymphoblastic leukaemia including intensi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Leukemia     Volume:  1     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  1987 Apr 
Date Detail:
Created Date:  1987-12-07     Completed Date:  1987-12-07     Revised Date:  2013-03-04    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  331-3     Citation Subset:  IM    
Affiliation:
Servizio di Chemio-Immunoterapia Ematologica, Ospedale S. Martino, Genova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Interferon Type I / therapeutic use*
Leukemia, Hairy Cell / pathology,  therapy*
Leukocyte Count
Platelet Count
Spleen / pathology
Chemical
Reg. No./Substance:
0/Interferon Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The treatment of hairy cell leukemia with alpha 2b-interferon: experience with 27 patients treated m...
Next Document:  Strategy for the treatment of hairy cell leukemia.